Posts tagged Compounding Bulk Drug Substances
FDA’s PCAC Votes in Favor of Six Peptides for Potential Inclusion on the 503A Bulks List: What Compounders Need to Know
FDA’s PCAC Votes in Favor of Six Peptides for Potential Inclusion on the 503A Bulks List: What Compounders Need to Know

On July 23-24, 2026, the U.S. Food and Drug Administration’s (FDA’s) Pharmacy Compounding Advisory Committee (PCAC) met to consider seven peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. PCAC voted in favor of including the free-base and acetate forms of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while voting against inclusion of Emideltide (DSIP). Vote outcomes were the same for the free-base and acetate forms of each substance. With peptide compounding at an important regulatory crossroads, it is worth unpacking what occurred during the July 2026 meeting, what the committee’s votes mean today, and what questions remain as FDA considers the next steps in the regulatory process.

Read More
503A, 503BAna AleksicPeptides, Compounding, Compounding Bulk Drug Substances
FDA Peptides Meeting July 2026: What Happens After the PCAC Vote
FDA Peptides Meeting July 2026: What Happens After the PCAC Vote

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides for potential inclusion on the 503A Bulks List. This discussion extends beyond headlines about “popular unproven chemicals.” It is a regulatory and drug safety matter with direct implications for compounders and patients nationwide. We examine which peptides will be reviewed, the regulatory steps that follow the PCAC meeting, and what the outcome could mean for patient access and the broader future of personalized medicine.

Read More
503A, 503BAmy SummersPeptides, Compounding, Compounding Bulk Drug Substances
Compounding Essentially a Copy FAQs
Compounding Essentially a Copy FAQs

Some of the most prevalent questions compounding pharmacies and 503B outsourcers ask have to do with the do’s and don’ts of compounding essential copies of drugs. To help compounders sift through the confusion and interpretation, we discuss the most frequently asked questions about compounding an essential copy of an approved drug and provide real life examples.

Read More
Amy SummersEssentially a Copy Guidance, Compounding Bulk Drug Substances, Pharmacy Compounding